坦度螺酮辅助治疗非糜烂性反流病的临床研究

Clinical studies of tandospirone in adjuvant therapy of non-erosive reflux disease

目的评价坦度螺酮辅助治疗非糜烂性反流病的临床疗效。方法整群选取该院收治的167例非糜烂性反流病患者,随机分为治疗组81例和对照组86例,对照组采用泮托拉唑联合莫沙比利治疗,治疗组在对照组基础上加用坦度螺酮。观察治疗后两组患者临床疗效以及RDQ评分。结果治疗结束后治疗组总有效率为90.38%,对照组为70.24%,治疗组总有效率高于对照组(P<0.05);两组治疗后烧心、反酸、胸痛、反食等症状均有所改善,治疗组RDQ评分明显低于对照组(P<0.05);两组均无明显不良反应发生。结论坦度螺酮辅助治疗非糜烂性反流病临床疗效明显,推荐用于合并焦虑抑郁情绪患者。

Objective To evaluate the efficacy of tandospirone in adjuvant therapy of non-erosive reflux disease. Methods A total of 167 patients with non-erosive reflux disease in our hospital,were randomly divided into therapeutic group （n=81,treating with pantoprazole plus mosapride）and control group（n=86,treating with tandospirone ,pantoprazole plus mosapride）. The clinical efficacy and RDQ score of the two groups were evaluated. Results The total effective rate was higher in the therapeutic group（90.38%） than in the control group （70.24%）. The symptoms of heartburn,reflux,chest pain and regurgitation were improved, and the RDQ score was significantly lower in the therapeutic group than the control group（P〈0.05）. There were no adverse events in two groups. Con-clusion The adjuvant therapy of Tandospirone has a significant effect in non-erosive reflux disease,which is recommended for pa-tients with depress and anxiety.